-DOCSTART- -X- O
RNA-based -X- _ O
approaches -X- _ O
have -X- _ O
provided -X- _ O
novel -X- _ O
alternatives -X- _ O
for -X- _ O
modern -X- _ O
drug -X- _ O
discovery. -X- _ O
The -X- _ O
application -X- _ O
of -X- _ O
RNA -X- _ O
as -X- _ O
therapeutic -X- _ O
agents -X- _ O
has -X- _ O
, -X- _ O
until -X- _ O
recently -X- _ O
, -X- _ O
been -X- _ O
hampered -X- _ O
by -X- _ O
issues -X- _ O
related -X- _ O
to -X- _ O
poor -X- _ O
delivery -X- _ O
and -X- _ O
stability -X- _ O
, -X- _ O
but -X- _ O
chemical -X- _ O
modifications -X- _ O
and -X- _ O
new -X- _ O
delivery -X- _ O
approaches -X- _ O
have -X- _ O
increased -X- _ O
progress. -X- _ O
Moreover -X- _ O
, -X- _ O
the -X- _ O
discovery -X- _ O
of -X- _ O
the -X- _ O
importance -X- _ O
of -X- _ O
RNA -X- _ O
in -X- _ O
gene -X- _ O
regulation -X- _ O
and -X- _ O
gene -X- _ O
silencing -X- _ O
has -X- _ O
revealed -X- _ O
new -X- _ O
drug -X- _ O
targets -X- _ O
, -X- _ O
especially -X- _ O
related -X- _ O
to -X- _ O
treatment -X- _ O
of -X- _ O
cancer -X- _ O
and -X- _ O
other -X- _ O
diseases. -X- _ O
Recent -X- _ O
engineering -X- _ O
of -X- _ O
small -X- _ B-Outcome
molecules -X- _ I-Outcome
designed -X- _ I-Outcome
from -X- _ I-Outcome
RNA -X- _ I-Outcome
sequences -X- _ I-Outcome
to -X- _ I-Outcome
target -X- _ I-Outcome
miRNAs -X- _ I-Outcome
opens -X- _ O
up -X- _ O
new -X- _ O
possibilities -X- _ O
in -X- _ O
drug -X- _ O
development. -X- _ O
Furthermore -X- _ O
, -X- _ O
RNA-based -X- _ B-Intervention
vaccines -X- _ I-Intervention
have -X- _ O
been -X- _ O
engineered -X- _ O
applying -X- _ O
RNA -X- _ O
virus -X- _ O
vectors -X- _ O
and -X- _ O
non-viral -X- _ O
delivery -X- _ O
for -X- _ O
vaccine -X- _ O
development -X- _ O
. -X- _ O

